25. Segment Information The Company has two reportable segments, the Generics segment and the Specialty segment. Generics develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals across a broad range of therapeutic categories. The Company's retail and institutional portfolio contains approximately 200 product families, many of which represent difficult-to-manufacture products or products that have a high barrier-to-entry, such as oncologics, anti-infectives and supportive care products for healthcare providers. Specialty delivers proprietary medicines to the U.S. market. The Company offers a growing portfolio in core therapeutic categories including central nervous system disorders, endocrinology, parasitic infections and other therapeutic areas. Our specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Specialty also has a number of product candidates that are in varying stages of development. The Companys chief operating decision maker evaluates the financial performance of the Companys segments based upon segment operating income (loss). Items below income (loss) from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Companys chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in "Corporate and Other." The Company does not report balance sheet information by segment since it is not reviewed by the Companys chief operating decision maker. The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct research and development expenses and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment (in thousands): Year Ended December 31, 2019 Generics (1) Specialty (1) Corporate and Other Total Company Net revenue $ 1,308,843 $ 317,530 $  $ 1,626,373 Cost of goods sold 984,782 162,432  1,147,214 Cost of goods sold impairment charges 119,145 7,017  126,162 Gross profit 204,916 148,081  352,997 Selling, general and administrative 68,883 79,665 141,050 289,598 Research and development 172,196 15,853  188,049 In-process research and development impairment charges 46,619   46,619 Acquisition, transaction-related and integration expenses 4,633 8,346 3,409 16,388 Restructuring and other charges 20,101 391 13,853 34,345 Intellectual property legal development expenses 13,193 1,045  14,238 Charges (gains) related to legal matters, net 12,442   12,442 Operating (loss) income $ (133,151 ) $ 42,781 $ (158,312 ) $ (248,682 ) (1) During the three months ended September 30, 2019, operating results for Oxymorphone were reclassified from Generics to Specialty, where it is sold as a non-promoted product. Prior period results have not been restated to reflect the reclassification. Year Ended December 31, 2018 Generics Specialty Corporate and Other Total Company Net revenue $ 1,439,031 $ 223,960 $  $ 1,662,991 Cost of goods sold 835,181 103,592  938,773 Cost of goods sold impairment charges 7,815   7,815 Gross profit 596,035 120,368  716,403 Selling, general and administrative 68,426 49,465 109,955 227,846 Research and development 183,412 10,778  194,190 In-process research and development impairment charges 39,259   39,259 Acquisition, transaction-related and integration expenses 114,622  107,196 221,818 Restructuring and other charges 33,943 4,076 18,394 56,413 Intellectual property legal development expenses 15,772 489  16,261 Charges (gains) related to legal matters, net (22,300 )  2,589 (19,711 ) Operating income (loss) $ 162,901 $ 55,560 $ (238,134 ) $ (19,673 ) Year Ended December 31, 2017 Generics Specialty Corporate and Other Total Company Net revenue $ 1,033,654 $  $  $ 1,033,654 Cost of goods sold 507,476   507,476 Gross profit 526,178   526,178 Selling, general and administrative 56,050  52,996 109,046 Research and development 171,420   171,420 Intellectual property legal development expenses 20,518   20,518 Charges (gains) related to legal matters, net (29,312 )   (29,312 ) Acquisition and transaction-related expenses   9,403 9,403 Operating income (loss) $ 307,502 $  $ (62,399 ) $ 245,103